Impact of OKT3 and polyclonal antibodies on symptomatic CMV infection in renal transplant recipients.
Yeung
S
S
Division of Nephrology, Department of Medicine, Princess Margaret Hospital, Kowloon, Hong Kong, People's Republic of China. yeungsj@yahoo.com
Tong
K L
KL
Chan
H W
HW
D000906:Antibodies / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000032:analysis; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology*; D004279:DNA, Viral / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000821:virology; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors
D000906:Antibodies; D000914:Antibodies, Viral; D000956:Antigens, Viral; D004279:DNA, Viral; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3